Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute [Yahoo! Finance]
Roivant Sciences Ltd. - Common Shares (ROIV)
Company Research
Source: Yahoo! Finance
March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a ?subsidiary of Roivant Sciences, and Arbutus ?Biopharma up to $2.25 billion to settle a ?long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on Tuesday. Under the deal, ?Moderna will ?pay $950 million upfront in July 2026, with an additional $1.3 billion ?that depends on the outcome of a separate legal appeal. In extended trading, ?Moderna's shares ?jumped more than ?10%, Arbutus rose ?11%, while Roivant was up about 1%. The deal resolves all U.S. and international legal actions accusing Moderna of using lipid nanoparticle, or LNP, a delivery ?technology owned by ?Genevant and Arbutus, without ?permission in ?its COVID-19 shot, Spikevax. LNP technology ?acts as a tiny ?protective shell ?that helps fragile mRNA molecules reach human cells intact, a key ?component that ?allows mRNA vaccines to work. (Reporting ?by Kamal Choudhury in Bengaluru; Editing ?by Al
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences (ROIV) was given a new $40.00 price target by Piper Sandler.MarketBeat
- Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure [Yahoo! Finance]Yahoo! Finance
- Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]USA TODAY
- Should Brepocitinib's New Trials and Batoclimab's Setback Require Action From Roivant Sciences (ROIV) Investors? [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 4/16/26 - Form 144/A
- 4/16/26 - Form 144
- 4/10/26 - Form 4
- ROIV's page on the SEC website